Description

• Title:
  Melatonin receptor agonists in neurodegenerative diseases and psychiatric disorders
• Creator:
  Dyrek, Nicola;
  Balwierz, Magdalena;
  Łata, Marcin;
  Kosińska, Agnieszka
• Description:
  Neurodegenerative and psychiatric diseases remain a therapeutic challenge. Mental illnesses such as depression and bipolar affective disorder lead to disruption of the diurnal rhythm of melatonin secretion and disruption of the sleep-wake axis. The use of new melatonergic drugs has received special attention in recent years. Selective melatoninergic M1 and M2 receptor agonists (tasimelteon, ramelteon) show a more favorable metabolic profile, better regulation of circadian rhythms, and effects on total sleep time and sleep quality compared to the already well-studied melatonin. In addition, these drugs show no addictive potential. Agomelatine, through its action on M1 and M2 receptors, as well as serotonergic 5-HT2C and 5-HT2B receptors, exhibits antidepressant, normothymic, and neuroprotective effects, providing primary therapy or adjunctive treatment.
• Object availability:
  free access
• Rights: https://creativecommons.org/licenses/by-nc-sa/4.0 ;
  Prawa autorskie (c) 2024 Nicola Dyrek, Magdalena Balwierz, Marcin Łata, Agnieszka Kosińska
• Date:
  2024.09.23
• Type:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Language:
  English
• Source:
  Quality in Sport; Tom 22 (2024); 54717;
  Quality in Sport; Vol. 22 (2024); 54717;
  2450-3118
• Format:
  application/pdf
• Publisher:
  University Center for Sports Research, Nicolaus Copernicus University, Torun, Poland
• Relation: https://apcz.umk.pl/QS/article/view/54717/39802
• Subject:
  melatonin;
  agomelatine;
  ramelteon;
  tasimelteon;
  melatoninergic receptors agonists
• Identifier: https://apcz.umk.pl/QS/article/view/54717
• Data provider:
  Akademicka Platforma Czasopism
• Can I use it?:
  seek permission
• Type:
  text